NGNE Neurogene
- 30.320
- -9.680-24.20%
- 30.100
- -0.220-0.73%
Neurogene News
Meridian Small Cap Growth Fund Trimmed Neurogene (NGNE) on Share Price Appreciation
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Quantum Corporation (NASDAQ:QMCO) fell sharply during Tuesday's session after the company reported worse-than-expected FY24 financial results and issued FY25 guidance below estimates.Quantum
Neurogene Down Over 22%, on Pace for Largest Percent Decrease Since June 2018 -- Data Talk
Neurogene Inc. ( NGNE ) is currently at $31.05, down $8.95 or 22.38% --Would be lowest close since May 13, 2024, when it closed at $30.64 --On pace for largest percent decrease since June 27, 2018,
Express News | Neurogene Shares Are Trading Lower. The Company Announced That the First Patient in Cohort 2 Received High-dose NGN-401 Gene Therapy in the Phase 1/2 Trial for Female Pediatric Patients With Rett Syndrome
Express News | Neurogene Announces First Patient Dosed in High-Dose Cohort of Ngn-401 Gene Therapy Clinical Trial for Rett Syndrome
Neurogene Initiated at Outperform by Baird
Neurogene Initiated at Outperform by Baird
Baird Initiates Coverage On Neurogene With Outperform Rating, Announces Price Target of $54
Baird analyst Joel Beatty initiates coverage on Neurogene (NASDAQ:NGNE) with a Outperform rating and announces Price Target of $54.
Baird Initiates Neurogene(NGNE.US) With Buy Rating, Announces Target Price $54
Baird analyst Joel Beatty initiates coverage on $Neurogene(NGNE.US)$ with a buy rating, and sets the target price at $54.According to TipRanks data, the analyst has a success rate of 46.7% and a total
Neurogene to Participate in Upcoming Conferences
Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will
H.C. Wainwright Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $51
H.C. Wainwright analyst Mitchell Kapoor maintains $Neurogene(NGNE.US)$ with a buy rating, and maintains the target price at $51.According to TipRanks data, the analyst has a success rate of 39.2% and
TD Cowen Maintains Neurogene(NGNE.US) With Buy Rating
TD Cowen analyst Ritu Baral maintains $Neurogene(NGNE.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 43.5% and a total average return of 7.4% over the past year.N
Express News | HC Wainwright & Co. Reiterates Buy on Neurogene, Maintains $51 Price Target
Express News | Neurogene Announces Ngn-401 Gene Therapy for Rett Syndrome Selected by FDA for Start Pilot Program
Taysha Gene Therapies Upgraded at Jefferies on Rett Syndrome Asset
Neurogene's Strong Pipeline and Financial Health Prompt Buy Rating
Express News | Neurogene Inc : Leerink Partners Cuts Target Price to $45 From $46
Neurogene Is Maintained at Buy by HC Wainwright & Co.
Neurogene Is Maintained at Buy by HC Wainwright & Co.
Express News | Neurogene Inc. : H.c. Wainwright Cuts Target Price to $51 From $55
Analysts Offer Insights on Healthcare Companies: Xencor (XNCR) and Neurogene (NGNE)
Neurogene | 10-Q: Quarterly report
Analysis
Price Target
No Data
